Alumis.png
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025 16:15 ET | Alumis Inc.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
January 30, 2025 07:00 ET | Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) --  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
cmi_logo.png
[Latest] Global Single Cell Multiomics Market Size/Share Worth USD 18.90 Billion by 2033 at a 19.58% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
January 30, 2025 03:30 ET | Custom Market Insights
Austin, TX, USA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Single Cell Multiomics Market Size, Trends and Insights By Technology...
JJ_Logo_SingleLine_Red_RGB.png
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology
January 23, 2025 05:45 ET | Janssen Cilag International NV
The first investigational FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a...
Straits Logo 1-01 (1).png
Allergy Treatment Market Size is Projected to Reach USD 64.65 billion by 2033, Growing at a CAGR of 6.46%: Straits Research
January 22, 2025 09:55 ET | Straits Research Private Limited - Garner Insights
New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Many of the population suffer from allergies, frequently associated with a low quality of life characterized by the constant fear of...
DMR Logo.png
Anti-CRP Antibody Market Is Expected To Reach A Revenue Of USD 363.1 Mn By 2033, At 7.9 % CAGR: Dimension Market Research
January 20, 2025 09:57 ET | Dimension Market Research
New York, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Market OverviewThe Global Anti-CRP Antibody Market is projected to reach USD 183.3 million by the end of 2024 and is expected to grow significantly,...
Figure 1
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
January 15, 2025 09:52 ET | Trethera Corporation
LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
January 14, 2025 07:00 ET | Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
Regeneron Logo.jpg
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025 06:30 ET | Regeneron Pharmaceuticals, Inc.
Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.
barinthuslogo.jpg
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
January 10, 2025 08:00 ET | Barinthus Biotherapeutics
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is...